Dr. Reddy’s (RDY) Laboratories and Senores Pharmaceuticals announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL Tablets of Merck Sharp and Dohme in the U.S. market. The product will be marketed by Dr. Reddy’s. “We are pleased to advance our growth with the launch of a limited-competition product. With our continuous focus on niche opportunities, we are proud to be the second generic to receive approval for this product,” stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited. Ivermectin Tablets, 3 mg brand and generic products, had U.S. sales of approximately $20M MAT for the twelve months ending in September 2024 according to IQVIA.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDY:
- Dr. Reddy’s Labs to Engage with Investors in New York
- Dr. Reddy’s Receives USFDA Observations Post Inspection
- Dr. Reddy’s Gains Strong Rating Amid Robust Growth
- Dr. Reddy’s Laboratories Reports Record Quarterly Growth
- Biotech Alert: Searches spiking for these stocks today
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
